| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6109953 | Journal of Hepatology | 2009 | 9 Pages |
Abstract
Treatment with sorafenib reduced PP, SMABF, and PSCBF in noncirrhotic rats with prehepatic PHT, without affecting systemic hemodynamics. Additional antiproliferative, anti-inflammatory, and antiangiogenic effects of sorafenib were identified.
Keywords
KDRIL6TIMP2FLT1MDKTGFβ1αSMAComplications of cirrhosisSphKSMABFPPVLMMP9JAG1CD61NPR1MAPK14TGFβR1Tbx4Mitogen-activated protein kinase 14smARPTGS1eNOSEGFTNFαTGFβPSCPHTMidkinePDGFCXCL1DMSOAngiogenesisintegrin β3α-smooth muscle actininterleukin 6Transforming growth factor βtumor necrosis factor αDimethyl sulfoxideendothelial nitric oxide synthetaseSorafenibepidermal growth factorsham operationVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)platelet-derived growth factorPortal pressureMatrix metalloproteinase 9Animal studyTissue inhibitor of metalloproteinase 2Portal hypertensionPERKPartial portal vein ligationchemokine (C-X-C motif) ligand 1vascular endothelial growth factor receptor 1vascular endothelial growth factor receptor 2
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Thomas Reiberger, Bernhard Angermayr, Philipp Schwabl, Natascha Rohr-Udilova, Markus Mitterhauser, Alfred Gangl, Markus Peck-Radosavljevic,